Abstract: Compositions in a form suitable for topical administration, which is water-based, contain a vasoconstrictor. The vasoconstrictor is chosen from brimonidine or salts thereof, in a solvent-based phase of polyethylene glycol in combination with propylene glycol and/or dimethyl sulfoxide (DMSO), a hydrophilic film-forming agent chosen from a polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone in a non-crosslinked, crosslinked or acetate form, taken alone or in combination, and glycerine which is in the form of a hydrogel. Methods for prevention and/or treatment of dermatitis resulting from radiation, notably in the context of a radiotherapy treatmen, involve administering the compositions to a patient in need thereof.

Abstract: A water-based composition in a form suitable for topical administration contains a vasoconstrictor and is in the form of an emulsion having liquid crystals. The vasoconstrictor is chosen from the group consisting of brimonidine or salts thereof, in a solvent-based phase. The solvent-based phase includes polyethylene glycol in combination with propylene glycol, a hydrophilic film-forming agent chosen from a polyvinylpyrrolidone/vinyl acetate copolymer, and polyvinylpyrrolidone in a non-crosslinked, crosslinked or acetate form, taken alone or in combination, glycerine, an emulsifier chosen from (i) the combination of PEG-75 stearate and glyceryl monostearate, and (ii) the combination of polyoxyethylene-20 sorbitan monosteearate (polysorbate-60) and cetostearyl alcohol, an oleic acid or an oleyl alcohol, and an oil phase suitable for obtaining the emulsion having liquid crystals.